Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3872096 | 0.91 | LMNA (0.60) | LMNATHRB | |
| Tetrahydrofuran SCHEMBL2260480 | 0.86 | LMNA (0.60) | LMNATHRB | |
| Tetrahydrofuran SCHEMBL9877354 | 0.86 | LMNA (0.60) | LMNATHRB | |
| SCHEMBL2702135 | 0.84 | LMNA (0.57) | LMNATHRB | |
| SCHEMBL6867778 | 0.84 | LMNA (0.57) | LMNATHRB | |
| Dioxane SCHEMBL7672675 | 0.80 | LMNA (0.67) | LMNATHRB | |
| SCHEMBL7847095 | 0.77 | LMNA (0.80) | LMNATHRB | |
| Cyclopropane SCHEMBL1406305 | 0.77 | LMNA (0.80) | LMNATHRB | |
| Fluoride SCHEMBL6012729 | 0.77 | — | — | |
| Ether SCHEMBL10359647 | 0.75 | TSHR (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216346-A1 | Substituted Chromenones, IRE1 Inhibitors, and Methods of Using Same | THE WISTAR INST (US) | 2024-07-04 | — | — | US | disclosed |
| US-11945789-B2 | Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-11833137-B2 | Substituted chromenones, IRE1 inhibitors, and methods of using same | THE WISTAR INSTITUTE (US) | 2023-12-05 | — | — | US | disclosed |
| EP-2952587-B1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | STRATOS GENOMICS INC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20210008043-A1 | Substituted Chromenones, IRE1 Inhibitors, and Methods of Using Same | NATIONAL INSTITUTES OF HEALTH | 2021-01-14 | — | — | US | disclosed |
| WO-2019195135-A1 | SUBSTITUTED CHROMENONES, IRE1 INHIBITORS, AND METHODS OF USING SAME | THE WISTAR INSTITUTE (US) | 2019-10-10 | — | — | WO | disclosed |
| US-10323013-B2 | Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20180334729-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | Roche Sequencing Solutions, Inc. | 2018-11-22 | — | — | US | disclosed |
| EP-2987864-B1 | METHOD FOR DETECTING AN ANALYTE | STRATOS GENOMICS INC (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20180087103-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION AND RELATED METHODS | Roche Sequencing Solutions, Inc. | 2018-03-29 | — | — | US | disclosed |
| US-8324360-B2 | High throughput nucleic acid sequencing by expansion | STRATOS GENOMICS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120088235-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION AND RELATED METHODS | STRATOS GENOMICS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120071330-A1 | MULTIPLEXED IDENTIFICATION OF NUCLEIC ACID SEQUENCES | STRATOS GENOMICS INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110251079-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | STRATOS GENOMICS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110237787-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | STRATOS GENOMICS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-7939259-B2 | High throughput nucleic acid sequencing by expansion | STRATOS GENOMICS, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20100297644-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY SPACING | STRATOS GENOMICS INC. (US) | 2010-11-25 | — | — | US | disclosed |
| CN-101711960-A | Method for preparing 1,3-dioxane acetal type dianion surface active agent | UNIV SHANXI | 2010-05-26 | — | — | CN | disclosed |
| CN-101711960-A | Method for preparing 1,3-dioxane acetal type dianion surface active agent | UNIV SHANXI | 2010-05-26 | — | — | CN | disclosed |
| US-20090035777-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | Roche Sequencing Solutions, Inc. | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10323013-B2 | Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof | XBP1, ERN1, SREBF1 | LMNA 1945/4885THRB 2151/4885 |
| US-20210008043-A1 | Substituted Chromenones, IRE1 Inhibitors, and Methods of Using Same | XBP1, ERN1, ERN2 | LMNA 1588/4885THRB 3057/4885 |
| US-20120088235-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION AND RELATED METHODS | POLRMT, POLM, NSUN2 | LMNA 1088/4885THRB 4045/4885 |
| US-11833137-B2 | Substituted chromenones, IRE1 inhibitors, and methods of using same | XBP1, ERN1, ERN2 | LMNA 1588/4885THRB 3057/4885 |
| US-20090035777-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | ERCC4, NUDT21, CPSF6 | LMNA 233/4885THRB 4149/4885 |
| US-20110237787-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | ERCC4, NUDT21, CPSF6 | LMNA 233/4885THRB 4149/4885 |
| US-11945789-B2 | Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof | XBP1, DDIT3, ERN1 | LMNA 1798/4885THRB 1692/4885 |
| US-20240216346-A1 | Substituted Chromenones, IRE1 Inhibitors, and Methods of Using Same | XBP1, ERN1, ERN2 | LMNA 1674/4885THRB 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.